Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 3:8:8.
doi: 10.1186/s13569-018-0094-x. eCollection 2018.

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

Rohan C Parikh  1 , Maria Lorenzo  2 , Lisa M Hess  3 , Sean D Candrilli  1 , Steven Nicol  3 , James A Kaye  4
Affiliations

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

Rohan C Parikh et al. Clin Sarcoma Res. .

Abstract

Background: To describe patient and tumor characteristics, treatments, and survival among older adults in the United States with advanced soft-tissue sarcoma (STS), across and by categories of specifically defined histologic subtypes.

Methods: We conducted a retrospective cohort analysis using the SEER. The study population comprised patients ≥ 65 years old with advanced STS (excluding osteosarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors) diagnosed from January 1, 2001 to December 31, 2011.

Results: Of 4274 study patients, 2103 (49.2%) were male. Mean age was 77.8 years, and 1539 (36.0%) had distant disease at initial diagnosis. The most common histologic categories were leiomyosarcoma (922[21.6%]), undifferentiated pleomorphic sarcoma (652[15.3%]), and liposarcoma (554[13.0%]). Overall, 1227 (28.7%) patients received first-line systemic therapy. Among these patients, 325 (26.5%) received docetaxel plus gemcitabine and 231 (18.8%) received doxorubicin alone. Only 476 patients received second-line therapy (11.1%), most commonly doxorubicin alone (n = 101). Median overall survival (95% confidence interval) from advanced STS diagnosis was 8.9 (8.3, 9.7) months.

Conclusions: Although previous studies of younger populations reported anthracycline-based therapy predominated in first line, our study of older advanced STS patients found that docetaxel plus gemcitabine was most commonly used. Despite variation by histologic category, prognosis remains poor for older adult patients with advanced STS.

Keywords: Chemotherapy; Observational study; Soft-tissue sarcoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Survival estimates from diagnosis of advanced soft-tissue sarcoma
See this image and copyright information in PMC

References

    1. Wibmer C, Leithner A, Zielonke N, Sperl M, Windhager R. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol. 2010;21(5):1106–1111. doi: 10.1093/annonc/mdp415. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. National Cancer Institute (NCI). Age-adjusted SEER incidence rates. https://seer.cancer.gov/faststats/selections.php?series=age. Accessed 10 Jan 2018.
    1. Schöffski P, Cornillie J, Wozniak A, Li H, Hompes D. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat. 2014;37(6):355–362. doi: 10.1159/000362631. - DOI - PubMed
    1. National Cancer Institute (NCI). Adult soft tissue sarcoma treatment (PDQ); 2017. https://www.cancer.gov/types/soft-tissue-sarcoma/patient/adult-soft-tiss.... Accessed 30 March 2017.